DGAP-News

PharmaSGP publishes H1 Report 2020 and confirms strong performance and positive outlook for the full year - Seite 3

Due to the large number of product launches planned, in particular the upcoming launches of PharmaSGP's first drugs in the French market, the Management Board is quite optimistic for the full year 2020. The Management Board expects to be able to increase the revenue growth rate as well as the EBIT margin of the first half of 2020. These expectations are based on the assumption that there will not be another comprehensive lockdown in the second half of 2020 in connection with the corona pandemic in PharmaSGP's target markets and that product launches proceed as planned.

The complete H1 report 2020 is available for download as of today at ir.sgp-pharma.com in the "Publications" section.
 

KPI OVERVIEW H1 2020 BY ANNUAL COMPARISON

Group figures (in € million)	H1 2019	H1 2020	CAGR
Revenues	31.6	33.8	7.2%
Adjusted1 EBIT	9.0	10.6	17.7%
Unadjusted EBIT	9.0	9.5	5.3%
Adjusted1 EBIT margin	28.7%	31.5%
Unadjusted EBIT margin	28.7%	28.2%
Revenues by regions (in € million)	H1 2019	H1 2020	CAGR
Germany	23.4	24.6	4.9%
Italy	3.4	4.1	21.1%
Other European countries	4.7	5.1	8.5%
Share of revenues by regions	H1 2019	H1 2020
Germany	74.2%	72.7%
Italy	10.8%	12.1%
Other European countries	15.0%	15.2%
Revenues by product category (in € million)	H1 2019	H1 2020	CAGR
Health Brands	23.6	28.6	21.5%
Beauty Brands	7.6	5.2	-31.8%

^[1] Adjusted for one-time effects of EUR 1.1 million that include consulting costs and fees for the Group's corporate and organizational structuring.